mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Competing Interest Statement

H.G., K.V., and F.Kl. are listed as inventors on pending patent application(s) on SARS-CoV- 2-neutralizing antibodies filed by the University of Cologne.

Funding Statement

This work was supported by grants from COVIM: NaFoUniMedCovid19 (FKZ: 01KX2021) (to L.E.S. and F.Kl.), the Federal Institute for Drugs and Medical Devices (V-2021.3 / 1503_68403 / 2021-2022) (to F.Ku. and L.E.S.), by the German Center for Infection Research (DZIF) (to F.Kl.), and the DFG CRC1279 and CRC1310 (to F.Kl.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

COVID-19-convalescent samples were obtained under protocols approved by the ethics committee (EC) of the Medical Faculty of the University of Cologne (16-054 and 20-1187). Samples from non-infected vaccinated individuals were obtained under protocols (EICOV, COVIMMUNIZE, and COVIM) approved by the EC of Charite - Universitaetsmedizin Berlin (EA4/245/20 and EA4/244/20; EICOV and COVIMMUNIZE), and by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and the EC of the state of Berlin (COVIM).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes